Back to all studies
RecruitingNCT05607654

The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression

This study is recruiting. It focuses on depression and currently lists participation information in China.

DepressionDeviceFrom 18 Years to 45 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT05607654. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

This study is looking at care and outcomes for people with Treatment-resistant Depression. Some participants may receive sham rTMS instead of the study treatment, and direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including The First Affiliated Hospital of Zhejiang University in Hangzhou. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: January 1, 2023
Recruitment status
Recruiting
Estimated enrollment
Not clearly listed
Sponsor
First Affiliated Hospital of Zhejiang University
Sponsor type
University
Study type
Device
Intervention type
Device / app / digital / technology
Study phase
Not clearly listed
Locations
China
Age range
From 18 Years to 45 Years
Official registry ID
NCT05607654
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT05607654. We help you review the study, but cannot decide medical eligibility.
Why this study may matter

Why this study may matter

This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in China.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with a sham comparison. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a device, app, or technology?

This appears to be a device / app / digital / technology study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Do I need to want to stop or reduce tobacco use to participate?

The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.

What would I likely need to do?

You may need to use a device, app, or digital tool for a defined period. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What should I check about data, monitoring, alerts, and daily use?

If the study uses a device, app, or digital tool, check what data is collected, who can access it, how often you need to use it, and what happens if the tool detects a concerning signal. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by First Affiliated Hospital of Zhejiang University, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
The Mechanisms of Underlying Accelerated Repetitive Transcranial. — Depression Clinical Trial | HopeStage